SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

TREX BIO, INC.

(Name of Issuer)

Common Stock par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

10/08/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons PFIZER INC. (13-5315170)	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially	5	Sole Voting Power 700,000.00

Owned by Each Reporting Person With:	6	Shared Voting Power 1,265,066.00
	7	Sole Dispositive Power 700,000.00
	8	Shared Dispositive Power 1,265,066.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 1,965,066.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.2 %
12		Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person: Percent of class outstanding represented by the amount in row (11) is based on 27,445,682 shares of Common Stock outstanding as of October 8, 2026 as set forth in the Issuer's prospectus filed with the United States Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on October 8, 2026.

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons PFIZER VENTURES (US) LLC (82-5524518)
2		Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3		Sec Use Only
4		Citizenship or Place of Organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 1,265,066.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 1,265,066.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 1,265,066.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

☐

Percent of class represented by amount in row (9)

11

4.6 %

Type of Reporting Person (See Instructions)

12

OO

Comment for Type of Reporting Person: Percent of class outstanding represented by the amount in row (11) is based on 27,445,682 shares of Common Stock outstanding as of October 8, 2026 as set forth in the Issuer's prospectus filed with the United States Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on October 8, 2026.

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

TREX BIO, INC.

Address of issuer's principal executive offices:

(b)

269 East Grand Avenue, Suite 300, South San Francisco, California, 94080

Item 2.

Name of person filing:

(a)

PFIZER INC.

Address or principal business office or, if none, residence:

(b)

66 Hudson Boulevard East, New York, NY 10001

Citizenship:

(c)

Delaware, US

Title of class of securities:

(d)

Common Stock par value $0.0001 per share

CUSIP No.:

(e)

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a)

See the respective responses of the Reporting Persons to Item 9 on the attached cover pages.

(b) Percent of class:

See the respective responses of the Reporting Persons to Item 11 on the attached cover pages. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See the respective responses of the Reporting Persons to Item 5 on the attached cover pages.

(ii) Shared power to vote or to direct the vote:

See the respective responses of the Reporting Persons to Item 6 on the attached cover pages.

(iii) Sole power to dispose or to direct the disposition of:

See the respective responses of the Reporting Persons to Item 7 on the attached cover pages.

(iv) Shared power to dispose or to direct the disposition of:

See the respective responses of the Reporting Persons to Item 8 on the attached cover pages.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

PFIZER INC. (13-5315170)

Signature: /s/ Madelyn D. Purcell
Name/Title: Madelyn D. Purcell/Assistant Secretary
Date: 10/16/2026

PFIZER VENTURES (US) LLC (82-5524518)

Signature: /s/ Madelyn D. Purcell
Name/Title: Madelyn D. Purcell/Assistant Secretary
Date: 10/16/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of October 16, 2026, by and between Pfizer and PVUS.

CUSIP No. 89531N100

Exhibit 99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 99.1, including subsequent amendments thereto, is filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated: October 16, 2026

PFIZER INC.

By: /s/ Madelyn D. Purcell
Name: Madelyn D. Purcell
Title: Assistant Secretary

PFIZER VENTURES (US) LLC

By: /s/ Madelyn D. Purcell
Name: Madelyn D. Purcell
Title: Assistant Secretary